Minimal Residual Disease-Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial

BACKGROUND: We sought to improve outcome of childhood acute myeloid leukemia (AML) by applying risk-directed therapy based on the genetic abnormalities of the leukemic cells and measurements of minimal residual disease (MRD) as determined by flow cytometry during treatment. METHODS: From October 13,...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Rubnitz, Jeffrey E., Inaba, Hiroto, Dahl, Gary, Ribeiro, Raul C., Bowman, W. Paul, Taub, Jeffrey, Pounds, Stanley, Razzouk, Bassem I, Lacayo, Norman J., Cao, Xueyuan, Meshinchi, Soheil, Degar, Barbara, Airewele, Gladstone, Raimondi, Susana C., Onciu, Mihaela, Coustan-Smith, Elaine, Downing, James R., Leung, Wing, Pui, Ching-Hon, Campana, Dario
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3171799/
https://ncbi.nlm.nih.gov/pubmed/20451454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(10)70090-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi